Decitabine is a hypomethylating agent with activity in myelodysplastic syndrome (MDS). It is largely unknown whether treatment with this drug before allo-SCT will increase the toxicity of the preparative regimen or otherwise affect the results of the transplant. We report the outcome of 17 patients with MDS with a median age of 55.5 years (range, 36-66 years) who underwent an allo-SCT (12 siblings, 5 unrelated) after prior therapy with decitabine. Preparative regimens consisted of fludarabine in combination with BU (n ¼ 8) or melphalan (n ¼ 9). The source of stem cells was marrow in four patients and peripheral blood (PB) in 13 patients. Thirteen patients were in CR within 100 days of transplant. With a median follow-up of 12 months (range, 3-35 months), 11 patients are alive; eight in CR and three with progressive disease. Prior therapy with hypomethylating agents did not increase toxicity and may improve the outcome of allogeneic transplant in MDS and should be evaluated in a prospective trial.
Introduction
Myelodysplastic syndromes (MDSs) are a group of disorders characterized by peripheral cytopenias and a propensity for progression to AML. The various MDS subtypes have a heterogeneous natural history ranging from indolent to rapid progression to AML. This heterogeneity is of pivotal importance in decision-making regarding therapeutic intervention. 1 Traditionally, supportive care and growth factors were the mainstay of therapy for the older patients with less-advanced forms of MDS, whereas cytotoxic agents as well as allogeneic transplantation were used to treat younger patients with high-risk disease. The recent approval by the United States Food and Drug Administration of three agents, lenalidomide (Revlimid), 5-azacytidine (Vidaza) and decitabine (Dacogen), has increased our therapeutic armamentarium for treating these patients. [2] [3] [4] Methylation of CpG dinucleotide islands in the human DNA, as maintained by the enzyme cytosine DNA methyltransferase, has an important role in the modulation of epigenetic modifications. 5 Hypermethylation of promoter regions has emerged as an important mechanism of suppression of expression of several genes putatively involved in the neoplastic transformation of hematopoietic SCT (HSCT). 6 The inhibition of the enzyme DNA methyltransferase by 5-azacytidine and decitabine is associated with the hypomethylation and reactivation of such tumor suppressor genes. Such an activation of silenced genes is believed to be responsible for the induction of terminal differentiation of the neoplastic cells leading to senescence and apoptosis. 7, 8 Laboratory studies carried out on the PB and BM cells of patients treated with decitabine have revealed phenotypic modifications of the leukemic cells, with a reduction of expression of CD13 and CD33, and an increase in the antigenic density of surface determinants of mature myeloid cells such as CD16 and CD11c, although it is unclear whether these phenomena occur in vivo. [9] [10] [11] It is interesting that the expression of MHC class I molecules, HLA-DR and b-2-microglobulin, on the surface of leukemic cells is markedly increased during therapy with decitabine, potentially increasing their susceptibility to immune surveillance mechanisms, and may result in increased susceptibility of MDS cells to a GVL effect. 10, 11 Little is known of the effect of prior therapy with these agents on the outcomes of allogeneic transplants. Here, we examine the outcome of allo-SCT in 17 patients with MDS who were treated with decitabine before transplant.
Materials and methods

Patients
Seventeen patients with a diagnosis of MDS were treated with decitabine as part of a phase II clinical trial that has been reported earlier. 12 All patients signed a consent form approved by the University of Texas-M D Anderson Cancer Center Institutional Review Board. Patient characteristics are summarized in Table 1 . They included 11 men and 6 women with a median age of 55.5 years (range, 36-66 years). Three patients had refractory anemia (RA), eight RA with excess blasts (RAEB) and six RA with excess blasts in transformation (RAEB-T) by the FrenchAmerican-British criteria. By the World Health Organization classification, six patients had AML with multilineage dysplasia, five RAEB-2, one RAEB-1, two refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS) and three RCMD. 13 At diagnosis, nine patients had intermediate-risk and eight high-risk disease by the international prognostic scoring system. Five patients had secondary MDS. Ten patients had complex cytogenetics, two had one abnormality and five were diploid. Karyotype was of high risk in 65% of the cases (n ¼ 11), intermediate in 6% (n ¼ 1) and good risk in 29% (n ¼ 5) ( Table 2 ). Four patients received other therapies including growth factors (n ¼ 4) or chemotherapy (n ¼ 1) before decitabine, whereas for 13 patients (77%) decitabine was the first MDS treatment.
Results
Outcome of therapy with decitabine
Fourteen patients received decitabine 20 mg/m 2 i.v. daily for 5 days for a median of five cycles (range, 1-19 cycles), and three patients had decitabine 10 mg/m 2 i.v. for 10 days. 12 The median duration of treatment with decitabine was 5.5 months (range, 1-24 months). Decitabine was well tolerated with reversible gastrointestinal toxicity and neutropenic infections as the main side effects. Definitions of response categories are described in the footnote for Table 1 . Best response to decitabine was CR in eight patients, PR in three patients, clinical benefit with hematological improvement in three patients, and progressive disease or no response in three patients. Cytogenetics did not correlate with responses to decitabine treatment in this small cohort ( Table 1 ). The median time between completion of decitabine therapy and transplant was 63 days (range, 30-124 days).
We recommended transplantation at the time of best response to the hypomethylating agent, depending on donor availability, patient preference or presence of comorbidities. This was the approach for all patients achieving remission with decitabine reported here. Patients who did not achieve a CR with decitabine were not necessarily treated at the time of best response owing to a variety of reasons, including donor procurement delays, referring physician and patient preference and so on.
Outcome of allogeneic transplant
The details of the transplant procedures are summarized in Table 2 . Donors were siblings in 12 patients (HLA-identical in 10, one-antigen mismatch in 1 and haploidentical in 1) and HLA-identical unrelated donors in five. The sources of stem cells were BM in four patients and apheresis product in 13 patients. All patients received fludarabine as a component of their conditioning regimen as described in Table 1 . A reduced-intensity conditioning regimen was used in nine patients, and eight patients received a myeloablative regimen. GVHD prophylaxis was with tacrolimus and MTX in 16 patients and ex vivo T-cell depletion in the haploidentical transplant. All patients signed an Institutional Review Board-approved consent before proceeding to the transplant on various institutional protocols. These studies were conducted according to the principles of the Declaration of Helsinki.
At transplant, seven patients were in CR, two in PR and eight had progressive disease. The median CD34 þ cell number was 4.49 Â 10 6 cells/kg (range, 0.58-10.1 Â 10 6 CD34 þ cells/kg). Sixteen patients engrafted and one patient (with a haploidentical donor) had engraftment failure. Median times to neutrophil and plt engraftment were 14 days (range, 10-30 days) and 16 days (range, 7-35 days), respectively. Eleven patients (65%) developed acute GVHD, two organs were involved in four and an isolated organ in seven. The GVHD was at maximum grade 3. Six patients developed chronic GVHD, two extensive and four limited. Other transplant-related toxicity included grade 2 gastrointestinal disturbances in 10 patients, arrhythmia in 1 patient and multi-organ failure leading to death in 1 patient. After 100 days of transplant, 13 patients were complete donor chimeras, 2 had mixed chimerism, 1 patient did not engraft and 1 patient was not evaluable because of early death. Seven patients were transplanted in CR, whereas 10 had evidence of disease at the time of HSCT. Six of 11 patients with poor-risk cytogenetics were in CR after HSCT. Two of seven patients in CR, and 6 of 10 with active disease at transplant are alive and disease-free (Table 2 ). Seven patients relapsed at a median time of 10 months (range, 2-33 months). With a median follow-up of 12 months (range, 3-35 months), 11 patients are alive, 8 in CR and 3 with progressive disease. Six patients have died, four after progression of disease, one from acute GVHD and one from sepsis.
Discussion
Despite the availability of new therapeutic options, treatment of MDS remains difficult with a relatively short duration of PFS and OS for patients with intermediate-and high-risk disease. Allo-SCT is the only curative treatment option for patients in MDS. However, it is associated with a significant risk of early mortality and significant morbidity. As a result, there is hesitance to use it as first-line treatment, except in younger patients with high-risk disease.
14 The median age of MDS patients at diagnosis is in the seventh to eighth decades of life, whereas most transplant series include patients in the fourth to sixth decades. 15, 16 Therefore, age and other known and unknown factors create a patient selection process that has to be taken into account when interpreting results of allogeneic transplantation in MDS. In addition, the lack of insurance coverage, donor availability and superimposed clinical comorbidities frequently limit the applicability of allogeneic HSCT to a minority of patients. 17 The increased use of hypomethylating /l and a plt count 4100 Â 10 9 /l; HI: meets all criteria for CR except for plt recovery to 4100 Â 10 9 /l; PR: as above except for the presence of 6-15% marrow blasts, or 50% reduction if o15% at start of treatment; CB: plts increase by 50% and to above 30 Â 10 9 /l untransfused (if lower than that pre-therapy); or granulocytes increase by 100% and above 10 9 /l (if lower than that pre therapy); or hemoglobin increase by 2 g per 100 ml; or transfusion independent; or splenomegaly reduction by 450%; or monocytosis reduction by 450% if pretreatment 45 Â agents will pose the question whether the outcomes of allogeneic HSCT will be affected by exposure to decitabine or azacitidine, the currently available drugs in this class. On the basis of our series of patients, toxicity does not seem to be increased by previous use of decitabine. In addition, disease 'downstaging' may improve outcomes of transplantation per se. It is unclear, however, whether transplant should be performed at the time of best response or whether it should be postponed until loss of response to decitabine is evident. We have shown here that an allo-SCT can be conducted safely after treatment with the hypomethylating agent decitabine, and have discussed the potential reasons why such an approach of hypomethylating therapy followed by transplant may improve the outcome of the transplant. There was no suggestion of changes in expected acute or chronic GVHD rates in our cohort. This strategy should be explored further in a prospective clinical trial where several cycles of hypomethylating therapy are followed by an allogeneic transplant.
